Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated:  7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
mi
from
NY, NY
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated: 7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
mi
from
NY, NY
Click here to add this to my saved trials
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated:  7/6/2015
University of Arizona
mi
from
Tucson, AZ
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated: 7/6/2015
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated:  7/6/2015
Stanford University
mi
from
Stanford, CA
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated: 7/6/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated:  7/6/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated: 7/6/2015
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated:  7/6/2015
Beth Israel Medical Center
mi
from
Boston, MA
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated: 7/6/2015
Beth Israel Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated:  7/6/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)
Status: Enrolling
Updated: 7/6/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Pharmacotherapy & CM for Opioid and Cocaine Dependence
Pharmacotherapy & CM for Opioid and Cocaine Dependence
Status: Enrolling
Updated:  7/7/2015
Department of Veterans Affairs
mi
from
West Haven, CT
Pharmacotherapy & CM for Opioid and Cocaine Dependence
Pharmacotherapy & CM for Opioid and Cocaine Dependence
Status: Enrolling
Updated: 7/7/2015
Department of Veterans Affairs
mi
from
West Haven, CT
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
University of California San Diego Medical Center
mi
from
San Diego, CA
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
Maple Grove Hospital
mi
from
Maple Grove, MN
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
Maple Grove Hospital
mi
from
Maple Grove, MN
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
North Memorial Hospital
mi
from
Robbinsdale, MN
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
North Memorial Hospital
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
St Paul Children's Hospital
mi
from
St Paul, MN
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
St Paul Children's Hospital
mi
from
St Paul, MN
Click here to add this to my saved trials
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated:  7/7/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Status: Enrolling
Updated: 7/7/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
Loess Hills Clinical Research Center
mi
from
Council Bluffs, IA
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
Loess Hills Clinical Research Center
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
UPMC Translational Research Center
mi
from
Pittsburg, PA
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
UPMC Translational Research Center
mi
from
Pittsburg, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
Medical University of South Carolina
mi
from
Charleston, SC
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  7/7/2015
Arizona Pulmonary Specialists, Ltd.
mi
from
Scottsdale, AZ
A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 7/7/2015
Arizona Pulmonary Specialists, Ltd.
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Andalusia, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Andalusia, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Anniston, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Athens, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Athens, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Birmingham, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Mesa, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Scottsdale, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Tucson, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Anaheim, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Carlsbad, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Lakewood, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Lakewood, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Los Angeles, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Pasadena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Pasedena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Pasedena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Poway, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Poway, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Sacramento, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
San Diego, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Tustin, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Tustin, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Colorado Springs, CO
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Denver, CO
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Fort Collins, CO
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Wheat Ridge, CO
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Danbury, CT
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Danbury, CT
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Waterbury, CT
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Brandon, FL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Brandon, FL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Clearwater, FL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Clearwater, FL
Click here to add this to my saved trials